# Fetal Hemoglobin Induction Treatment Metformin

> **NCT02981329** · EARLY_PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 37 (actual)

## Conditions studied

- Sickle Cell Anemia
- Sickle Cell Disease
- Hemoglobin Disorder

## Interventions

- **DRUG:** Metformin
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT02981329
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2020-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981329, "Fetal Hemoglobin Induction Treatment Metformin". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02981329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*